drugset / Trial / NCT05864014

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

NCT05864014

Phase 3 Active not recruiting 213 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.

Timeline

Start
2023-04-25
Primary completion
2025-03-03
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule

Indications